CDK4/6 inhibitor
Clinical trials for CDK4/6 inhibitor explained in plain language.
Never miss a new study
Get alerted when new CDK4/6 inhibitor trials appear
Sign up with your email to follow new studies for CDK4/6 inhibitor, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets Hard-to-Treat brain tumors
Disease control Recruiting nowThis early-stage trial tests two oral drugs, IN10018 and dalpiciclib, in 24 adults with progressive meningiomas (brain tumors that keep growing despite treatment). The main goal is to check safety and find the best dose. Researchers will also see if the combination can shrink tum…
Matched conditions: CDK4/6 INHIBITOR
Phase 1 • Sponsor: Capital Medical University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo aims to keep early breast cancer from returning
Disease control Recruiting nowThis study is testing whether adding the drug dalpiciclib to standard hormone therapy can help prevent breast cancer from coming back in women with early-stage HR+/HER2- breast cancer. About 2,000 women will receive either a higher dose for 2 years or a lower dose for 3 years, al…
Matched conditions: CDK4/6 INHIBITOR
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New study tracks breast cancer return in patients on targeted therapy
Knowledge-focused Recruiting nowThis study observes 750 people with a common type of breast cancer who have already been treated with surgery and are now taking CDK4/6 inhibitors to lower the risk of cancer coming back. Researchers will track how many patients experience a relapse and how well they do over time…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC